Jane Street Group, LLC Rubius Therapeutics, Inc. Transaction History

Jane Street Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $19,478 - $54,625	-42,345 Reduced 64.03%	23,784 $10,000
Q2 2022 Aug 16, 2022	BUY	$0.79 - $5.98 $22,407 - $169,616	28,364 Added 75.11%	66,129 $56,000
Q1 2022 May 17, 2022	SELL	$4.25 - $10.4 $191,092 - $467,615	-44,963 Reduced 54.35%	37,765 $208,000
Q1 2021 May 18, 2021	BUY	$8.02 - $32.01 $575,443 - $2.3 Million	71,751 Added 653.65%	82,728 $2.19 Million
Q4 2020 Feb 17, 2021	SELL	$4.23 - $8.73 $83,182 - $171,675	-19,665 Reduced 64.18%	10,977 $83,000
Q3 2020 Nov 17, 2020	BUY	$4.65 - $6.25 $142,485 - $191,512	30,642 New	30,642 $154,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.